BMS
Agilent Expands CE-IVD Mark for Companion Dx Tests Alongside BMS European Opdivo Approvals
Agilent obtained a CE-IVD mark for expanded use of its PD-L1 IHC 28-8 pharmDx assay to guide cancer treatment with Bristol Myers Squibb's Opdivo.
Roche, Bristol Myers Squibb Partner on Digital Pathology Algorithms, Assays for Cancer Diagnosis
Under the collaboration, Roche is developing an artificial intelligence-based image analysis algorithm to help pathologists interpret its Ventana PD-L1 (SP142) Assay.
Invitae, Pharma Firms Partner to Develop Standard MRD Panel for AML Clinical Trials
Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.
Illumina CEO Discusses Pan-Cancer IVD Assay, CDx Collaborations at JP Morgan
The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.
Grail Inks Deals With Amgen, AstraZeneca, Bristol Myers Squibb for MRD Test Development
The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.